Loomis, Sayles & Company’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,189,601
| Closed | -$60M | – | 768 |
|
|
2024
Q3 | $60M | Buy |
2,189,601
+1,326,497
| +154% | +$36.3M | 0.08% | 101 |
|
|
2024
Q2 | $21.1M | Buy |
+863,104
| New | +$21.1M | 0.03% | 251 |
|
|
2019
Q2 | – | Sell |
-475,806
| Closed | -$15.8M | – | 683 |
|
|
2019
Q1 | $15.8M | Sell |
475,806
-26,401
| -5% | -$877K | 0.03% | 246 |
|
|
2018
Q4 | $14.6M | Buy |
502,207
+501,969
| +210,911% | +$14.6M | 0.03% | 228 |
|
|
2018
Q3 | $11K | Hold |
238
| – | – | ﹤0.01% | 793 |
|
|
2018
Q2 | $9K | Buy |
238
+7
| +3% | +$265 | ﹤0.01% | 807 |
|
|
2018
Q1 | $7K | Sell |
231
-922
| -80% | -$27.9K | ﹤0.01% | 839 |
|
|
2017
Q4 | $40K | Buy |
1,153
+395
| +52% | +$13.7K | ﹤0.01% | 626 |
|
|
2017
Q3 | $27K | Buy |
758
+166
| +28% | +$5.91K | ﹤0.01% | 705 |
|
|
2017
Q2 | $15K | Buy |
592
+83
| +16% | +$2.1K | ﹤0.01% | 773 |
|
|
2017
Q1 | $10K | Hold |
509
| – | – | ﹤0.01% | 804 |
|
|
2016
Q4 | $8K | Buy |
509
+33
| +7% | +$519 | ﹤0.01% | 858 |
|
|
2016
Q3 | $10K | Buy |
476
+54
| +13% | +$1.13K | ﹤0.01% | 766 |
|
|
2016
Q2 | $13K | Buy |
422
+126
| +43% | +$3.88K | ﹤0.01% | 700 |
|
|
2016
Q1 | $11K | Buy |
296
+252
| +573% | +$9.37K | ﹤0.01% | 810 |
|
|
2015
Q4 | $2K | Sell |
44
-194
| -82% | -$8.82K | ﹤0.01% | 990 |
|
|
2015
Q3 | $9K | Buy |
+238
| New | +$9K | ﹤0.01% | 912 |
|
|
2013
Q4 | – | Sell |
-551,696
| Closed | -$13M | – | 777 |
|
|
2013
Q3 | $13M | Sell |
551,696
-2,997
| -0.5% | -$70.4K | 0.04% | 448 |
|
|
2013
Q2 | $14.9K | Buy |
+554,693
| New | +$14.9K | 0.05% | 385 |
|